The development of granulocyte colony-stimulating factors (GCSF) revolutionized the use of chemotherapy, reducing the incidence of severe neutropenia in patients receiving myelosuppressive chemotherapy, subsequently allowing more patients to receive adequate dose intensity chemotherapy, and led to improved overall survival. Here, CSF3 is linked to neutropenia.